- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02212808
Antimicrobial Stewardship in Community Hospitals
A Multicenter, 3-Stage Cluster Randomized Historically-Controlled Crossover Trial to Determine the Feasibility and Outcomes From Two Antimicrobial Stewardship Interventions in Community Hospitals
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a three-stage cluster randomized historically controlled crossover trial designed to evaluate the feasibility of the implementation of two AS strategies. Four community hospitals in the Duke Infection Control Outreach Network (DICON) will be recruited for this study. Ideally, hospitals will have no teaching affiliation, bed size <300, and no existing antimicrobial formulary restriction and preauthorization or post-antibiotic prescription review practices in place at study start.
Data will be obtained from the four community hospitals in three stages. In stage 1, historical data from each hospital will be collected for the year prior to study initiation from all participating hospitals. These data are used as a control representing current practice. In stage 2, the four hospitals will be divided into two pairs based upon bed size. One hospital from each pair will be randomly assigned to a six-month period of antimicrobial restriction and preauthorization (Strategy 1; stage 2) followed by a six-month period of post-antibiotic prescription review (Strategy 2; stage 3). The other two hospitals will undergo Strategy 2 in stage 2 followed by Strategy 1 in stage 3 to help alleviate the concern for seasonal/temporal effects when comparing the strategies to each other. A one-month wash out will be performed between each stage. Three antibiotics will be specifically targeted for intervention: anti-pseudomonal carbapenem of choice at the study hospital, vancomycin, and piperacillin-tazobactam. Utilization of alternative antimicrobials, including fluoroquinolones, cephalosporins, and anti-methicillin resistant Staphylococcus aureus (anti MRSA) systemic antimicrobials (e.g., nafcillin, daptomycin, linezolid, ceftaroline, clindamycin, and trimethoprim-sulfamethoxazole (TMP-SMX)) will also be collected. All study hospitals will have electronic systems that track antimicrobial prescriptions through orders, electronic medication administration records (eMAR), bar-coded medication administration (BCMA), or dispensing data.
Hospitals will have dedicated clinical pharmacist time for preauthorization or post-antibiotic review for the three targeted antibiotics in each arm of the study. Pharmacists (PharmDs) at each site will receive standardized training by study personnel in order to address common questions and anticipated arguments, and to establish a robust knowledge base regarding the targeted antimicrobials (anti-pseudomonal carbapenem of choice at the study hospital, vancomycin, and piperacillin-tazobactam). They will also be trained in conflict management.
Study personnel will provide suggested criteria for appropriate use of each targeted drug. Hospital P&T committees will review, edit (if desired), and approve hospital-specific protocols for appropriate use criteria for each study drug. Pharmacists will be provided with specific clinical pathways for urinary tract infections (UTIs), community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), bacteremia, and "other" uses of targeted antimicrobial. Clinical pathways will be developed jointly by study personnel and based on Centers for Disease Control and Prevention pilot projects. Clinical pharmacists will determine appropriateness of therapy based on study clinical pathways, their baseline knowledge, and acquired knowledge derived by training from study personnel. Time spent performing the two stewardship strategies will be supported by grant funds. The designated pharmacist will be involved in two critical components of the protocol: a) completing the intervention and b) documenting the outcome of the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-All adult and pediatric patients admitted to the study hospital who are prescribed targeted or alternative antimicrobial agent(s) will have data collected from their medical records.
Exclusion Criteria:
- Any patient not meeting the criteria above will be excluded.
- Patients who receive < 24 hours of surgical prophylaxis with a targeted or alternative antimicrobial will be excluded.
- Finally, any patient followed by an Infectious Disease consultant will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Antimicrobial restriction
All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm.
Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial.
The pharmacist will then decide if the targeted antibiotic is approved or denied.
If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
|
All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm.
Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial.
The pharmacist will then decide if the targeted antibiotic is approved or denied.
If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
The pharmacist will document this interaction in the REDCap database.
|
Experimental: Post-antimicrobial prescription review
All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written.
The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours).
The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart.
Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified.
If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
|
All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written.
The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart.
Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified.
If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
The interaction will be documented in the REDCap database.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility 1 - Intervention Approval
Time Frame: Prior to implementation, estimated length of 3 months up to 6 months
|
To evaluate administrative steps required for protocol approval of two stewardship intervention strategies at study hospitals.
|
Prior to implementation, estimated length of 3 months up to 6 months
|
Feasibility 2 - PharmD training
Time Frame: Prior to implementation, estimated length of 1 months up to 2 months
|
To evaluate the steps required for training of local PharmD(s) to administer the two stewardship strategies.
|
Prior to implementation, estimated length of 1 months up to 2 months
|
Feasibility 3 - PharmD Time
Time Frame: Day of Intervention, expected length of 20 hours per week up to 52 weeks
|
To estimate and compare the time required of the pharmacist to administer the different strategies.
|
Day of Intervention, expected length of 20 hours per week up to 52 weeks
|
Feasibility 4 - Resource Utilization
Time Frame: During hospitalization, an expected length of 14 days, up to 30 days
|
To estimate and compare the resource utilization of each strategy, including pharmacist time and cost of antibiotics.
|
During hospitalization, an expected length of 14 days, up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antimicrobial utilization - Days of Therapy
Time Frame: During Hospitalization, an expected length of 14 days, up to 30 days
|
To compare the total days of therapy of targeted and alternative antibiotics between each strategy.
|
During Hospitalization, an expected length of 14 days, up to 30 days
|
Patient Outcomes
Time Frame: During Hospitalization, an expected length of 14 days, up to 30 days
|
To compare patient-specific outcomes between each strategy including but not limited to total hospital days, death and ICU admission
|
During Hospitalization, an expected length of 14 days, up to 30 days
|
Pharmacist/Physician Perceptions
Time Frame: Within 1 month of completion of intervention arm
|
To compare the prescriber and pharmacist perceptions of the two stewardship strategies
|
Within 1 month of completion of intervention arm
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Deverick J Anderson, MD, MPH, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00052362
- 1UM1AI104681-01 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibiotic Stewardship in Community Hospitals
-
ARCIM Institute Academic Research in Complementary...Gemeinschaftskrankenhaus Herdecke, GermanyRecruitingCommunity Acquired Pneumonia in Children | Antibiotic StewardshipGermany
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationAntibiotic Stewardship | Implementation Science | Blood Culture RatesUnited States
-
Intermountain Health Care, Inc.CompletedAntibiotic Stewardship | Inappropriate Prescribing | Anti-Bacterial Agents
-
Duke UniversityCompletedAntibiotic StewardshipUnited States
-
The University of QueenslandNational Health and Medical Research Council, AustraliaRecruitingAntibiotics Causing Adverse Effects in Therapeutic Use | Antimicrobial StewardshipAustralia
-
University Hospital, Basel, SwitzerlandCompleted
-
The Cleveland ClinicRecruitingCommunity-Acquired Pneumonia | Antimicrobial Stewardship | Point-of-Care TestingUnited States
-
Hannover Medical SchoolCompletedCommunity-acquired Pneumonia | Antimicrobial Stewardship | Exacerbation Copd | Lower Respiratory Tract and Lung Infections | Exacerbation of Allergic AsthmaGermany
-
Benaroya Research InstituteNorthwell Health; Stony Brook University; Virginia Mason Hospital/Medical Center and other collaboratorsRecruitingOveractive Bladder | Antibiotic Stewardship | UTI | Onabotulinumtoxin AUnited States
-
Hacettepe UniversityTurkish Society of Clinical Entral & Parenteral NutritionCompletedMicrobial Community in Breast MilkTurkey
Clinical Trials on Antimicrobial restriction
-
PfizerUniversity of Adelaide; Royal Adelaide HospitalCompleted
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Fundación Pública Andaluza para la gestión de la...Completed
-
Rochal Industries LLCThe University of Texas Health Science Center at San Antonio; Brooke Army Medical... and other collaboratorsNot yet recruiting
-
Ottawa Heart Institute Research CorporationRecruitingPost-Op ComplicationCanada
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Associação Fundo de Incentivo...Completed
-
University of South CarolinaCompleted
-
Federal University of Minas GeraisRecruiting
-
University of SurreyCompletedMuscle Soreness | Muscle Strength | Muscle DamageUnited Kingdom